Wall Street analysts expect Cutera, Inc. (NASDAQ:CUTR) to announce sales of $20.20 million for the current quarter, according to Zacks. Two analysts have provided estimates for Cutera’s earnings, with the highest sales estimate coming in at $22.50 million and the lowest estimate coming in at $17.90 million. Cutera posted sales of $47.77 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 57.7%. The company is expected to issue its next earnings report on Thursday, August 13th.
According to Zacks, analysts expect that Cutera will report full-year sales of $132.45 million for the current financial year, with estimates ranging from $127.10 million to $137.80 million. For the next financial year, analysts forecast that the company will post sales of $189.60 million, with estimates ranging from $182.80 million to $196.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that follow Cutera.
Cutera (NASDAQ:CUTR) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.36). Cutera had a negative return on equity of 39.71% and a negative net margin of 9.30%. The business had revenue of $32.24 million for the quarter, compared to the consensus estimate of $35.35 million.
Shares of CUTR stock traded down $0.71 during trading hours on Monday, hitting $11.60. 516,197 shares of the company’s stock were exchanged, compared to its average volume of 330,527. Cutera has a 52 week low of $9.07 and a 52 week high of $39.15. The stock has a market cap of $214.97 million, a price-to-earnings ratio of -10.00 and a beta of 1.46. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.47 and a quick ratio of 0.76. The stock’s 50-day moving average is $13.39 and its 200-day moving average is $21.72.
In related news, Director J Daniel Plants purchased 95,238 shares of the business’s stock in a transaction dated Tuesday, April 21st. The shares were bought at an average price of $10.50 per share, with a total value of $999,999.00. Following the purchase, the director now directly owns 15,873 shares in the company, valued at approximately $166,666.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.30% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. raised its holdings in Cutera by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 114,516 shares of the medical device company’s stock worth $4,101,000 after purchasing an additional 711 shares during the period. Rhumbline Advisers raised its stake in Cutera by 6.4% during the 4th quarter. Rhumbline Advisers now owns 43,923 shares of the medical device company’s stock worth $1,573,000 after buying an additional 2,652 shares during the period. Swiss National Bank bought a new position in Cutera during the fourth quarter worth about $777,000. State Street Corp lifted its holdings in Cutera by 11.4% during the fourth quarter. State Street Corp now owns 519,042 shares of the medical device company’s stock worth $18,587,000 after acquiring an additional 53,285 shares in the last quarter. Finally, Crossmark Global Holdings Inc. acquired a new position in Cutera in the fourth quarter valued at about $222,000. Institutional investors own 79.38% of the company’s stock.
Cutera Company Profile
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Featured Article: Economic Bubble
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.